This article is more than 5 years old. Information may no longer be current.

Biosimilar to infliximab approved for use in Korea

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Samsung Bioepis Co. Ltd. announced Renflexis, its biosimilar to infliximab, has been approved by Korea’s Ministry of Food and Drug Safety for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis both in adults and children, psoriatic arthritis and psoriasis.

“We look forward to the introduction of Renflexis in Korea, where patients suffering from autoimmune diseases will soon have access to an affordable, high-quality biologic treatment option,” Christopher Hansung Ko, president and chief executive officer of Samsung Bioepis, said in a press release. “With an extensive pipeline of biosimilars on the way, we will continue to leverage our strengths in product development and quality assurance to bring these life-enhancing medications to patients who need them most.”

Samsung Bioepis has commercial agreements with Biogen and Merck related to its release of biosimilar medications.

Reference:

www.samsungbioepis.com